Analysts expect Agios Pharmaceuticals, Inc. to report revenue of 51.18 M for Q3 26, against a range of 48.79 M to 53.56 M. The most recent reported quarter, Q2 26, came in at 44.74 M, a 60.6% beat against the 27.86 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 9.00 M | 10.70 M | 8.70 M | 12.50 M | 12.90 M | 19.97 M | 20.75 M | 44.74 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 10.58 M | 9.15 M | 9.75 M | 10.54 M | 11.47 M | 12.45 M | 14.38 M | 29.82 M | 53.56 M | 73.27 M | 76.29 M | 91.50 M | 93.53 M | 109.87 M | 127.52 M | 137.76 M | ||||||||||
| Low Estimate | 9.20 M | 8.59 M | 8.65 M | 9.73 M | 10.78 M | 10.43 M | 12.97 M | 25.89 M | 48.79 M | 61.03 M | 65.45 M | 85.06 M | 79.80 M | 96.00 M | 107.18 M | 116.17 M | ||||||||||
| Consensus Estimate | 9.89 M | 8.87 M | 9.20 M | 10.14 M | 11.12 M | 11.44 M | 13.67 M | 27.86 M | 51.18 M | 67.15 M | 70.87 M | 88.28 M | 86.67 M | 102.94 M | 117.35 M | 126.97 M |
Analysts expect Agios Pharmaceuticals, Inc. to report earnings per share of -1.15 for Q3 26, against a range of -1.25 to -1.05. The most recent reported quarter, Q2 26, came in at -1.69, a 6.3% miss against the -1.59 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 16.22 | -1.44 | -1.55 | -1.93 | -1.78 | -1.86 | -1.69 | -1.69 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 16.60 | -1.49 | -1.55 | -1.62 | -1.79 | -1.96 | -1.54 | -1.44 | -1.05 | -1.10 | -0.95 | -0.81 | -2.26 | -3.70 | 0.83 | 1.59 | ||||||||||
| Low Estimate | 15.30 | -1.73 | -1.75 | -1.90 | -2.17 | -2.16 | -1.86 | -1.74 | -1.25 | -1.18 | -1.05 | -0.93 | -2.76 | -4.30 | 0.73 | 1.47 | ||||||||||
| Consensus Estimate | 15.95 | -1.61 | -1.65 | -1.76 | -1.98 | -2.06 | -1.70 | -1.59 | -1.15 | -1.14 | -1.00 | -0.87 | -2.51 | -4.00 | 0.78 | 1.53 |
Pull Wall Street consensus for Agios Pharmaceuticals, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=AGIO&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "AGIO", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=AGIO&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();